Biological effects and clinical efficacy of a topical Toll-like receptor 7 agonist in seasonal allergic rhinitis: a parallel group controlled phase IIa study

  title={Biological effects and clinical efficacy of a topical Toll-like receptor 7 agonist in seasonal allergic rhinitis: a parallel group controlled phase IIa study},
  author={Lennart Greiff and Cecilia Ahlstr{\"o}m-Emanuelsson and Mikaela Alen{\"a}s and Gun Almqvist and Morgan Andersson and Anders Cervin and J Dolata and Sam Lindgren and Anders M{\aa}rtensson and Barbara W. Young and Henrik Widegren},
  journal={Inflammation Research},
Objective and designThe purpose of the study was to examine effects of pre-treatment with a Toll-like receptor 7 (TLR7) agonist (AZD8848) in allergic rhinitis and to evaluate clinical effects of two dosing regimens.SubjectsThe study involved 83 patients with allergic rhinitis. Data on effects of AZD8848 on symptoms were analysed with data from a previous study (n = 68) of identical double blind, parallel group design (NCT00770003).TreatmentThe treatment involved intranasal AZD8848 20 µg three… 
Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study
In patients with allergic asthma, TLR7 agonists could potentially reduce allergen responsiveness by stimulating Type 1 interferon responses to down-regulate the dominant Th2 responses.
First‐in‐Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well‐Tolerated
Nonclinical data and phase I clinical profile of an inhaled TLR9 agonist, AZD1419, a C‐type CpG designed to induce interferon in the lung support its continued development as a potentially disease‐modifying therapeutic in asthma.
Toll-Like Receptor 7-Targeted Therapy in Respiratory Disease
In animal models, synthetic TLR7 agonists reduce airway hyperreactivity, eosinophilic inflammation, and airway remodeling while decreasing Th2-associated cytokines while reducing viral titers when given during an active airway infection.
Upregulated Expression of Toll-Like Receptor 7 in Peripheral Blood Basophils of Patients With Allergic Rhinitis
The percentage of TLR7+ basophils andTLR7 expression intensity in a single basophil are both increased in the blood of patients with AR, indicating that basophiles likely contribute to the pathogenesis of AR via TLR 7.
EAACI Allergen Immunotherapy User's Guide
This user's guide reviews current knowledge and aims to provide clinical guidance to healthcare professionals taking care of children undergoing allergen immunotherapy to improve the patient's adherence to the treatment.
Allergen Immunotherapy in Children User’s Guide
This user's guide reviews current knowledge and aims to provide clinical guidance to healthcare professionals taking care of children undergoing allergen immunotherapy.
Nasal administration of a probiotic assemblage in allergic rhinitis: A randomised placebo‐controlled crossover trial
Whether a topical/nasal administration of a probiotic assemblage (PA) affects quality of life, symptoms and signs of allergic rhinitis in a nasal allergen challenge (NAC) model is examined.
Targeting Antiviral Pathways for Treatment of Allergic Diseases.
A growing body of evidence indicates that the allergic milieu induces deficient antiviral responses in multiple cell types, likely contributing to disease pathogenesis.
IgE-mediated regulation of IL-10 and type I interferon enhances rhinovirus-induced Th2 priming by primary human monocytes
It is demonstrated that IgE crosslinking of RV-exposed monocytes enhances monocyte-driven Th2 priming, suggesting an additional mechanism by which two clinically significant risk factors for allergic disease exacerbations – IgE-mediated stimulation and rhinovirus infection, may synergistically promote Th2 differentiation and allergic inflammation.


Safety of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis.
  • T. Casale, Jean Kessler, F. Romero
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2006
Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis
Repeated intranasal stimulation of Toll-like receptor 7 by AZD8848 was safe and produced a sustained reduction in the responsiveness to allergen in allergic rhinitis.
Effects of a dual CCR3 and H1-antagonist on symptoms and eosinophilic inflammation in allergic rhinitis
AZD3778 exerts anti-eosinophil and symptom-reducing effects in allergic rhinitis and part of this effect can likely be attributed to CCR3-antagonism.
The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.
Immunomodulatory Effects of Viral TLR Ligands on Experimental Asthma Depend on the Additive Effects of IL-12 and IL-101
TLR-3 or TLR-7 activation by viral TLR ligands has both preventive as well as suppressive effects on experimental asthma which is mediated by the additive effects of IL-12 and IL-10.
Mechanism of Action of Inhibition of Allergic Immune Responses by a Novel Antedrug TLR7 Agonist
It is demonstrated that local type I IFN signaling and plasmacytoid dendritic cells, but not Th1 immune responses, are required for in vivo efficacy against murine airway Th2-driven eosinophilia.
Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses.
It is demonstrated that 1018 ISS is safe and pharmacologically active in the respiratory tract of asthmatics but, at this dose regimen, did not inhibit a fall in FEV or other key features of the response to inhaled allergen challenge.
TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway.
It is shown that treatment with a synthetic Toll-like receptor 7 (TLR7) ligand (S-28463, a member of the imidazoquinoline family) prevents development of the asthmatic phenotype, and this results clearly demonstrate the anti-inflammatory effect of imdazoquinolines in an allergic asthma model as well as the clinical potential of TLR7 ligands in the treatment of allergic diseases.
Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides.
This is the first report of a treatment that inhibits allergic lung inflammation in presensitized animals for a prolonged period and thus has relevance to the development of an effective long term treatment for asthma.
Chronic asthma-induced airway remodeling is prevented by toll-like receptor-7/8 ligand S28463.
Treatment with S28463 is able to prevent the development of goblet cell hyperplasia and increases in airway smooth muscle mass, and that this effect is at least partially mediated by inhibiting proliferation ofGoblet and smooth muscle cells, respectively.